You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《新股消息》再鼎醫藥(09688.HK)今日起招股 入場費為32,726.5元
阿思達克 09-17 09:01
再鼎醫藥(09688.HK)公布來港第二上市招股詳情,計劃發售1,056.41萬股,當中約7.3%作公開發售,最高發售價為648元,一手50股,入場費為32,726.49元。由今日(17日)至下周二(22日)公開招股,預計於9月28日上市。摩根大通、高盛及花旗為聯席保薦人。

公司預計,集資淨額約為66.14億元,當中約46.2%用於研發核心產品;11.8%預期將為進行中及計劃臨床試驗以及管線中其他候選藥物的準備中註冊備案撥資;25%預期將用於探索新的全球授權及合作機會等;7%預期將用於持續投資及擴大公司內部研發產品管線以及在全球招聘及培訓高端人才;餘下10%為營運資金及其他一般企業用途撥資。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account